208 related articles for article (PubMed ID: 35363510)
1. Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial.
Eckstein OS; Allen CE; Williams PM; Roy-Chowdhuri S; Patton DR; Coffey B; Reid JM; Piao J; Saguilig L; Alonzo TA; Berg SL; Ramirez NC; Jaju A; Mhlanga J; Fox E; Hawkins DS; Mooney MM; Takebe N; Tricoli JV; Janeway KA; Seibel NL; Parsons DW
J Clin Oncol; 2022 Jul; 40(20):2235-2245. PubMed ID: 35363510
[TBL] [Abstract][Full Text] [Related]
2. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.
Fangusaro J; Onar-Thomas A; Young Poussaint T; Wu S; Ligon AH; Lindeman N; Banerjee A; Packer RJ; Kilburn LB; Goldman S; Pollack IF; Qaddoumi I; Jakacki RI; Fisher PG; Dhall G; Baxter P; Kreissman SG; Stewart CF; Jones DTW; Pfister SM; Vezina G; Stern JS; Panigrahy A; Patay Z; Tamrazi B; Jones JY; Haque SS; Enterline DS; Cha S; Fisher MJ; Doyle LA; Smith M; Dunkel IJ; Fouladi M
Lancet Oncol; 2019 Jul; 20(7):1011-1022. PubMed ID: 31151904
[TBL] [Abstract][Full Text] [Related]
3. A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study.
Banerjee A; Jakacki RI; Onar-Thomas A; Wu S; Nicolaides T; Young Poussaint T; Fangusaro J; Phillips J; Perry A; Turner D; Prados M; Packer RJ; Qaddoumi I; Gururangan S; Pollack IF; Goldman S; Doyle LA; Stewart CF; Boyett JM; Kun LE; Fouladi M
Neuro Oncol; 2017 Aug; 19(8):1135-1144. PubMed ID: 28339824
[TBL] [Abstract][Full Text] [Related]
4. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers.
Bekaii-Saab T; Phelps MA; Li X; Saji M; Goff L; Kauh JS; O'Neil BH; Balsom S; Balint C; Liersemann R; Vasko VV; Bloomston M; Marsh W; Doyle LA; Ellison G; Grever M; Ringel MD; Villalona-Calero MA
J Clin Oncol; 2011 Jun; 29(17):2357-63. PubMed ID: 21519026
[TBL] [Abstract][Full Text] [Related]
5. LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration.
van Tilburg CM; Kilburn LB; Perreault S; Schmidt R; Azizi AA; Cruz-Martínez O; Zápotocký M; Scheinemann K; Meeteren AYNS; Sehested A; Opocher E; Driever PH; Avula S; Ziegler DS; Capper D; Koch A; Sahm F; Qiu J; Tsao LP; Blackman SC; Manley P; Milde T; Witt R; Jones DTW; Hargrave D; Witt O
BMC Cancer; 2024 Jan; 24(1):147. PubMed ID: 38291372
[TBL] [Abstract][Full Text] [Related]
6. Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C.
Chi SN; Yi JS; Williams PM; Roy-Chowdhuri S; Patton DR; Coffey BD; Reid JM; Piao J; Saguilig L; Alonzo TA; Berg SL; Ramirez NC; Jaju A; Mhlanga JC; Fox E; Hawkins DS; Mooney MM; Takebe N; Tricoli JV; Janeway KA; Seibel NL; Parsons DW
J Natl Cancer Inst; 2023 Nov; 115(11):1355-1363. PubMed ID: 37228094
[TBL] [Abstract][Full Text] [Related]
7. A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01.
Perreault S; Larouche V; Tabori U; Hawkin C; Lippé S; Ellezam B; Décarie JC; Théoret Y; Métras MÉ; Sultan S; Cantin É; Routhier MÈ; Caru M; Legault G; Bouffet É; Lafay-Cousin L; Hukin J; Erker C; Jabado N
BMC Cancer; 2019 Dec; 19(1):1250. PubMed ID: 31881853
[TBL] [Abstract][Full Text] [Related]
8. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.
Kirkwood JM; Bastholt L; Robert C; Sosman J; Larkin J; Hersey P; Middleton M; Cantarini M; Zazulina V; Kemsley K; Dummer R
Clin Cancer Res; 2012 Jan; 18(2):555-67. PubMed ID: 22048237
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer.
Deming DA; Cavalcante LL; Lubner SJ; Mulkerin DL; LoConte NK; Eickhoff JC; Kolesar JM; Fioravanti S; Greten TF; Compton K; Doyle AG; Wilding G; Duffy A; Liu G
Invest New Drugs; 2016 Apr; 34(2):168-75. PubMed ID: 26666244
[TBL] [Abstract][Full Text] [Related]
10. Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.
Dombi E; Baldwin A; Marcus LJ; Fisher MJ; Weiss B; Kim A; Whitcomb P; Martin S; Aschbacher-Smith LE; Rizvi TA; Wu J; Ershler R; Wolters P; Therrien J; Glod J; Belasco JB; Schorry E; Brofferio A; Starosta AJ; Gillespie A; Doyle AL; Ratner N; Widemann BC
N Engl J Med; 2016 Dec; 375(26):2550-2560. PubMed ID: 28029918
[TBL] [Abstract][Full Text] [Related]
11. Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements.
Hayes DN; Lucas AS; Tanvetyanon T; Krzyzanowska MK; Chung CH; Murphy BA; Gilbert J; Mehra R; Moore DT; Sheikh A; Hoskins J; Hayward MC; Zhao N; O'Connor W; Weck KE; Cohen RB; Cohen EE
Clin Cancer Res; 2012 Apr; 18(7):2056-65. PubMed ID: 22241789
[TBL] [Abstract][Full Text] [Related]
12. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.
Jänne PA; Shaw AT; Pereira JR; Jeannin G; Vansteenkiste J; Barrios C; Franke FA; Grinsted L; Zazulina V; Smith P; Smith I; Crinò L
Lancet Oncol; 2013 Jan; 14(1):38-47. PubMed ID: 23200175
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRAS
Kenney C; Kunst T; Webb S; Christina D; Arrowood C; Steinberg SM; Mettu NB; Kim EJ; Rudloff U
Invest New Drugs; 2021 Jun; 39(3):821-828. PubMed ID: 33405090
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.
Jain N; Curran E; Iyengar NM; Diaz-Flores E; Kunnavakkam R; Popplewell L; Kirschbaum MH; Karrison T; Erba HP; Green M; Poire X; Koval G; Shannon K; Reddy PL; Joseph L; Atallah EL; Dy P; Thomas SP; Smith SE; Doyle LA; Stadler WM; Larson RA; Stock W; Odenike O
Clin Cancer Res; 2014 Jan; 20(2):490-8. PubMed ID: 24178622
[TBL] [Abstract][Full Text] [Related]
15. Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer.
van Brummelen EMJ; Huijberts S; van Herpen C; Desar I; Opdam F; van Geel R; Marchetti S; Steeghs N; Monkhorst K; Thijssen B; Rosing H; Huitema A; Beijnen J; Bernards R; Schellens J
Oncologist; 2021 Apr; 26(4):290-e545. PubMed ID: 33296125
[TBL] [Abstract][Full Text] [Related]
16. Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma.
Patel SP; Lazar AJ; Papadopoulos NE; Liu P; Infante JR; Glass MR; Vaughn CS; LoRusso PM; Cohen RB; Davies MA; Kim KB
Cancer; 2013 Feb; 119(4):799-805. PubMed ID: 22972589
[TBL] [Abstract][Full Text] [Related]
17. Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer.
Krishnamurthy A; Dasari A; Noonan AM; Mehnert JM; Lockhart AC; Leong S; Capasso A; Stein MN; Sanoff HK; Lee JJ; Hansen A; Malhotra U; Rippke S; Gustafson DL; Pitts TM; Ellison K; Davis SL; Messersmith WA; Eckhardt SG; Lieu CH
Cancer Res; 2018 Sep; 78(18):5398-5407. PubMed ID: 30042150
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma.
Catalanotti F; Solit DB; Pulitzer MP; Berger MF; Scott SN; Iyriboz T; Lacouture ME; Panageas KS; Wolchok JD; Carvajal RD; Schwartz GK; Rosen N; Chapman PB
Clin Cancer Res; 2013 Apr; 19(8):2257-64. PubMed ID: 23444215
[TBL] [Abstract][Full Text] [Related]
19. Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.
Carter CA; Rajan A; Keen C; Szabo E; Khozin S; Thomas A; Brzezniak C; Guha U; Doyle LA; Steinberg SM; Xi L; Raffeld M; Tomita Y; Lee MJ; Lee S; Trepel JB; Reckamp KL; Koehler S; Gitlitz B; Salgia R; Gandara D; Vokes E; Giaccone G
Ann Oncol; 2016 Apr; 27(4):693-9. PubMed ID: 26802155
[TBL] [Abstract][Full Text] [Related]
20. Targeting the mitogen‑activated protein kinase kinase and protein kinase A pathways overcomes acquired resistance to Selumetinib in low‑grade glioma cells.
Melotti L; Meco D; Battaglia A; Buzzonetti A; Martini M; Ruggiero A; Scambia G; Riccardi R
Oncol Rep; 2021 Feb; 45(2):752-763. PubMed ID: 33416182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
